

Teva's Austedo drops out of 2024 blockbuster running on Tourette's failure



Elizabeth Cairns

Tourette's syndrome, like most neurological conditions, has proven resistant to pharmacological intervention, so the failure of Teva's attempt to extend Austedo into this disorder might not be wholly surprising - unless you are an equity analyst. The sellside had forecast 2024 Austedo revenues in Tourette's of \$175m, around 17% of the VMAT2 inhibitor's total sales that year. But Artists 1, a phase II/III study, and the phase III Artists 2 have both failed to show a reduction in motor and phonic tics with Austedo over placebo in children with moderate to severe Tourette's. Loss of the potential Tourette's sales means that Austedo could miss the sellside's overall 2024 blockbuster forecasts. The twin trial misses also leave the pipeline for Tourette's in a pretty dismal state. Data on Neurocrine's VMAT2 inhibitor Ingrezza and Lundbeck's Lu AG06466 should come this year, and on Otsuka's antipsychotic Abilify, which already has Tourette's on its label, in 2021, but the omens for many are not good; no significant banks have yet been willing to assign sales for these drugs in Tourette's.

Selected active projects in Tourette's

Project	Mechanism	Company	Trial details
Marketed			
Abilify	Partial 5-HT _{1A} , D2 agonist & 5-HT ₂ antagonist	Otsuka	NCT03661983 (Data due 2021)
Phase II/III			
Austedo	VMAT2 inhibitor	Teva/Nuvelution	NCT03452943 (Artists1, failed) NCT03571256 (Artists2, failed)
Ingrezza	VMAT2 inhibitor	Neurocrine	NCT03530293 (T-Force Platinum, update due Q2) NCT03325010 (T-Force Gold, failed)
Phase II			
Lu AG06466	MGLL inhibitor	Lundbeck (ex Abide)	NCT03625453 (data due 2020)
Ecopipam	D1 & D5 antagonist	Emalex Biosciences	No active trials
THX-110	Cannabinoid receptor agonist	Therapix Biosciences	NCT03651726 (not yet recruiting)

Source: EvaluatePharma.

My Chart

My Untitled Chart

